Handelsavisen
prelaunch
Companies Healthcare TAKE.NS
TA
TAKE.NS NSE (India) Biotechnology & Medical Research

Take.Ns

$25,60
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
182,5 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TAKE.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Business. TAKE.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityHealthcare Diagnostics
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
182,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TAKE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TAKE.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TAKE.NS operates in the healthcare diagnostics industry, providing diagnostic solutions and related services to healthcare providers and patients.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityHealthcare Diagnostics
    AI synthesis
    GENERATED

    TAKE.NS has a strong liquidity position, as evidenced by its current ratio of 1.48, indicating that it has sufficient current assets to cover its current liabilities. The company's cash and equivalents amount to INR 29.5 million, which provides a buffer against short-term obligations. However, the company's operating cash flow is negative at INR -164.5 million, suggesting that its core operations are not generating positive cash flow.

    In terms of profitability, TAKE.NS has a return on equity (ROE) of 1.83 and a return on assets (ROA) of 1.03, which are relatively low compared to industry benchmarks. The company reported a net income of INR 374.7 million, but this was accompanied by an operating loss of INR 74.7 million, indicating that operational inefficiencies or high costs are impacting its bottom line.

    The company's revenue is not disclosed, but its financials suggest a concentration in a single business line or geographic region. The absence of detailed segment or geographic revenue breakdowns in the provided data makes it difficult to assess diversification. The company's capital structure is relatively simple, with no long-term debt and a debt-to-equity ratio of 0, indicating a conservative approach to financing.

    Looking at the growth trajectory, TAKE.NS has not provided specific forward-looking revenue or earnings guidance. The company's free cash flow of INR 7.44 million is modest, and with no capital expenditures reported, it appears that the company is not investing in expansion or new projects. The lack of capital expenditure may indicate a focus on maintaining current operations rather than pursuing growth opportunities.

    The risk assessment for TAKE.NS indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong equity position reduce the likelihood of financial distress. However, the negative operating cash flow is a concern and may require monitoring in the future.

    Recent events and filings do not show any significant changes in the company's financial or operational status. The company's financial statements do not indicate any recent major transactions, acquisitions, or strategic shifts that would impact its future performance.

    Key takeaways
    • TAKE.NS has a strong liquidity position with a current ratio of 1.48 and no long-term debt.
    • The company's profitability is mixed, with a net income of INR 374.7 million but an operating loss of INR 74.7 million.
    • TAKE.NS has a conservative capital structure with a debt-to-equity ratio of 0.
    • The company's growth trajectory is unclear due to the lack of capital expenditures and forward-looking guidance.
    • The risk assessment indicates low liquidity and dilution risks, but the negative operating cash flow is a concern.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $25,60
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $205.3M
    Net cash
    $29.5M
    Current ratio
    1.5
    Debt / equity
    0.0
    ROA
    1.0%
    ROE
    1.8%
    Cash conversion
    -44.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE182,5 %Best in class
    D/E0,00Above median
    Cash Conv-0,44Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • TAKE.NS Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TAKE.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage